icon-folder.gif   Conference Reports for NATAP  
 
  AASLD
The Liver Meeting
Boston MA
November 2016
Back grey_arrow_rt.gif
 
 
 
Comparison of Markers of Bone Turnover Demonstrates Less Changes in CHB Patients Receiving Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate
 
 
  Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
 
Wan-Long Chuang,1Wai-Kay Seto,2 Tetsuro Inokuma,3 Fusao Ikeda,4 Teresa Antonia Santantonio,5 John F. Flaherty,6 Kyungpil Kim,6 Anuj Gaggar,6 G Mani Subramanian,6 Franšois Habersetzer,7 Alnoor Ramji,8 Shrikant Mukewar,9 Henry Lik-Yuen Chan,10 Maurizia R. Brunetto11
1Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan; 2Queen Mary Hospital, Hong Kong; 3Kobe City Medical Center General Hospital, Kobe City, Japan; 4Okayama University Hospital, Okayama City, Japan; 5Azienda Ospedaliera Universitaria Ospedali Riuniti, Foggia, Italy;
6Gilead Sciences, Inc., Foster City, CA; 7H˘pital Civil, Strasbourg, France; 8Pacific Gastroenterology Associates & GI Research Institute, Vancouver, British Columbia, Canada; 9Midas Multispeciality Hospital, Nagpur, India; 10Prince of Wales Hospital, Hong Kong; 11Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy

HCV1

HCV2

HCV3

HCV4

HCV5

References
1. Fung S, et al. J Hepatol In press; 2. Gill US, et al. J Infect Dis 2015;374-82; 3. Babusis D, et al. Mol Pharm 2013;10:459-66; 4. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906; 5. Murakami E, et al. Antimicrob Agents Chemother 2015;59:3563-9; 6. Agarwal K, et al. J Hepatol 2015;62:533-40; 7. Sax P, et al. Lancet 2015;385:2606-15; 8. Mills A, et al. Lancet Infect Dis 2016;16:43-52; 9. Terrault NA, et al. Hepatology 2016;63:261-83 10. Kanis JA, et al. Osteoporosis Int 2008;19:385-97.